Key Insights

Highlights

Treatment Research

3 treatments under study, led by Temozolomide Tace

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05647954Phase 3UnknownPrimary

A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver

Showing all 1 trials

Research Network

Common Treatments

  • Temozolomide Tace1
  • Pembrolizumab1
  • Hx008 Tace1

Active Sponsors

  • Taizhou Hanzhong biomedical co. LTD1

Top Investigators

  • Jun Guo, MD1

    Peking University Cancer Hospital & Institute

Activity Timeline